Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?

Breast Cancer

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Lancet Oncol

Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Viale G, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Gelber R, Loibl S

doi: 10.1016/S1470-2045(25)00546-7

Genitourinary Cancer

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis

BJU Int

Roessler N, Miszczyk M, Gontero P, Dematteis A, Miyajima K, Inoue S, Oberneder K, von Deimling M, Schuettfort VM, Vetterlein MW, Szabados B, Rajwa P, Karakiewicz PI, Teoh JY, Fisch M, Shariat SF

doi: 10.1111/bju.70214

Gastrointestinal Cancer

Incomplete neoadjuvant chemo(radio)therapy negatively impacts pathological response and overall survival in locally advanced esophageal cancer

Eur J Cancer

Kamp D, Noya S, Mook S, Ruurda JP, Hillegersberg RV, Wang J, Jeene P, Brosens LAA, May AM, Verhoeven RHA, Laarhoven HWMV, Haj Mohammad N

doi: 10.1016/j.ejca.2025.115538

Gastrointestinal Cancer

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Eur J Cancer

Leone AG, Petrelli F, Klempner SJ, Smyth EC, Sundar R, Lordick F, Lorenzen S, Masetti M, Obermannova R, Alsina M, Janjigian YY, Pietrantonio F

doi: 10.1016/j.ejca.2025.116155

Further Publications

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Ann Oncol

Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G

doi: 10.1016/j.annonc.2025.03.019

Genitourinary Cancer

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

Lancet Oncol

Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO, International Neoadjuvant Kidney Cancer Consortium

doi: 10.1016/S1470-2045(25)00345-6

Skin Cancer

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Ann Oncol

Rawson RV, Maher NG, Menzies AM, Lo SN, Ardakani NM, Jackett LA, Vergara IA, Pennington TE, Shannon KF, Ch'ng S, Gonzalez M, Burton EM, Lucas MW, Reijers ILM, Rozeman EA, Gyorki DE, Sandhu S, Carlino MS, Howle J, Khattak M, Van der Westhuizen A, Andrews MC, Atkinson V, van Akkooi ACJ, Spillane AJ, Saw RPM, van de Wiel BA, Blank CU, Long GV, Tetzlaff MT, Scolyer RA

doi: 10.1016/j.annonc.2025.10.1237

Gastrointestinal Cancer

Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial

Eur J Cancer

Michiel Zeeuw J, Kemna R, Ali M, van Eck S, Wesdorp NJ, Roor J, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, Grunhagen DJ, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, Verhoef C, de Wilt JHW, Buffart TE, Swijnenburg RJ, Punt CJA, Verpalen IM, Stoker J, Huiskens J, Kazemier G, CAIRO5 research group

doi: 10.1016/j.ejca.2025.115738

Lung, Respiratory and Thoracic Cancer

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

N Engl J Med

Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N, CheckMate 816 Investigators

doi: 10.1056/NEJMoa2502931

Related content

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis

Incomplete neoadjuvant chemo(radio)therapy negatively impacts pathological response and overall survival in locally advanced esophageal cancer

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer